NY-CELONIS
29.3.2022 12:02:13 CEST | Business Wire | Press release
Celonis , the global leader in execution management, announced the acquisition of Process Analytics Factory GmbH (PAF), a leading provider of process mining insights for Microsoft Power BI. This acquisition will enable millions of Microsoft Power Platform users to utilize Celonis’ market leading Execution Management System (EMS) for process mining, automation, and collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220329005245/en/
The acquisition of PAF is part of Celonis’ strategy to enable companies everywhere and in all industries to use process mining within the Celonis EMS to reveal and fix process inefficiencies. Celonis is committed to empowering users of the top automation, collaboration, and workflow platforms to run their businesses using Celonis’ unique process insights and intelligent, targeted actions.
The PAFnow process mining product is completely integrated into Microsoft Power BI and Microsoft Office 365 for the analysis, visualization and optimization of almost any process. 97 percent of the Fortune 500, and over 260,000 companies globally, use Microsoft Power BI.
The Celonis EMS combines, in one integrated cloud platform, real-time data, process intelligence, and targeted action to impact top, bottom, and greenline business performance at speed. Customers looking to get full clarity on how their business processes are running - whether across supply chains, shared service centers, or system landscapes - can now benefit from the unique and advanced capabilities of the Celonis EMS within their familiar Microsoft environments.
Maximilian Gerbert, project lead at Mercedes-Benz Management Consulting, said: “We - the Digital Accelerator of Mercedes-Benz - are a data-driven department with a business intelligence strategy built over years, but once we brought process mining into our BI infrastructure we were able to see the full picture and identify process inefficiencies throughout our company that we never could before. When supply chain issues come up, we use insights from process mining within BI to pinpoint the bottlenecks and take action to fix them — before they impact our cash flow and our customer experience. We are excited by the news of the Celonis acquisition and the ability to leverage the powerful capabilities of the Celonis EMS within our Microsoft environment.”
"It’s great to see Celonis and PAF join forces,” said Linus Linder, Head of IT at Muller - Die lila Logistik Service GmbH. “Now we can benefit from the real-time data, process intelligence, and targeted action in the Celonis EMS within our familiar Microsoft Power BI environment."
The rapid adoption of the Celonis EMS comes on the heels of a generational shift to use process insights and intelligence to change how businesses are run.
According to Gartner® the market for hyper-automation software will reach nearly $860 billion by 20251 . But many businesses do not maximize the value of their digital investments because they lack insight into outdated processes holding back business operations. According to a Forrester report commissioned by Celonis, process mining has hit an inflection point in 2022 as decision makers demand better execution by finding and fixing process inefficiencies.
“Since we started 11 years ago, the Celonis mission has always been the same - to help our customers reach the full potential of their business performance by removing process inefficiencies - and that requires Celonis to be everywhere,” said Alex Rinke, co-CEO and co-founder of Celonis. “The PAF acquisition enables the millions of users of the Microsoft Power Platform to use Celonis’ unique data and intelligent insights to power analytics, automation, and collaboration.”
“This combination leverages the strength of Celonis market leadership with the foundation that PAF has created in the Microsoft Power Platform. This allows our companies to build the bridge between the Microsoft Power Platform and the Celonis Execution Management System,” said Tobias Rother, CEO and founder of PAF. “We are thrilled to help put Celonis into the hands of such a large and fast-growing community of business leaders.”
“In our inaugural HFS SaaS XXV 2022 report we ranked Celonis as the top private SaaS company in Overall Rank, Business Value Creation, Partner Engagement, and OneOffice Alignment,” said Phil Fersht, CEO and Chief Analyst of HFS Research. “The acquisition of PAF demonstrates why Celonis is ranked alongside Microsoft, Salesforce, Amazon, Adobe, and Google for shaping the future of native automation, data, and process design. Celonis is strategically moving its unique process data and intelligent insights into the world’s largest work, automation, and analytics platforms.”
"The purpose of process mining is to gain a fact-based understanding of business process variance and inefficiency to systematically improve processes to maximize performance while aligning with the overall goals of a business. Embedding process mining into common analytics platforms makes it easier for teams to work together using familiar tools,” said Maureen Fleming, Program Vice President for the IDC Intelligent Process Automation Market Research and Advisory Service.
The PAFnow software capabilities will debut in Celonis Experiences at Celonis World Tour 2022 . Celonis Experiences will showcase how customers can seamlessly integrate Celonis EMS with Microsoft Power BI reporting, collaborate with Microsoft Teams, and trigger flows in Microsoft Power Automate.
About Celonis
Celonis helps organizations to execute on their data. Powered by its market-leading process mining core, the Celonis Execution Management System provides a set of applications, a developer studio and platform capabilities for business executives and users to eliminate billions in corporate inefficiencies, provide better customer experience and reduce carbon emissions. Celonis has thousands of implementations in global customers and is headquartered in Munich, Germany and New York City, USA with 20 offices worldwide.
© 2022 Celonis SE. All rights reserved. Celonis, Execution Management System, EMS and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
1 Gartner, Forecast Analysis: Hyperautomation of Enablement Software, Worldwide, Cathy Tornbohm, Fabrizio Biscotti, Rachel Chippendale, March 22, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005245/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom